Cardioprotective effects of Hypericum triquetrifolium Turra. against cyclophosphamide related cardiotoxicity in rats

被引:8
作者
Cetik Yildiz, Songul [1 ]
Keskin, Cumali [2 ]
Sahinturk, Varol [3 ]
Ayhanci, Adnan [4 ]
机构
[1] Mardin Artuklu Univ, Vocat Higher Sch Hlth Serv, Dept Med Serv & Tech, Mardin, Turkey
[2] Mardin Artuklu Univ, Sch Hlth, Dept Nutr & Dietet, TR-47200 Mardin, Turkey
[3] Eskisehir Osmangazi Univ, Fac Med, Dept Histol & Embryol, Eskisehir, Turkey
[4] Eskisehir Osmangazi Univ, Fac Sci, Dept Biol, TR-26480 Eskisehir, Turkey
来源
JOURNAL OF RESEARCH IN PHARMACY | 2018年 / 22卷 / 03期
关键词
Cardiotoxicity; cyclophosphamide; cardioprotective effects; Hypericum triquetrifolium Turra;
D O I
10.12991/jrp.2018.77
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cyclophosphamide (CYP) is commonly used as anticancer agent but its usage is limited by cardiotoxic side effects such as dose-dependent cardiac damage, morphologically defined necrosis and bleeding. Hypericum triquetrifolium Turra. (HT) shows anti-oxidative and anticarciogenic properties with its rich phenolic contents. The current study was designed to investigate the possible protective effect of HT on CYP-induced cardiotoxicity. Albino rats were randomly divided into 9 groups, each included 7 animals. Serum creatine kinase-MB (CK-MB), malondialdehyde (MDA), aspartate transaminase (AST), glutathione (GSH), total antioxidant (TAC) and total oxidant capacity (TOC) levels were investigated. Furthermore, the cardiac tissue samples were investigated histopatologically. While the levels of serum CK-MB, MDA, AST and TOC were high, the levels of serum GSH and TAC levels were low in the CYP groups. It was also observed that CYP-induced cardiotoxicity was dose dependent. In the treatment with CYP plus HT doses there was observed an essential decrease in the CYP cardiotoxicity; decreased cell damage and oxidative stress parameters and also increased GSH and TAC levels. Based on our findings, it can be proposed that HT seed methanol extract was a strong candidate in preventing the CYP-induced cardiotoxicity.
引用
收藏
页码:374 / 385
页数:12
相关论文
共 38 条
[21]   DL-α-lipoic acid ameliorates cyclophosphamide induced cardiac mitochondrial injury [J].
Mythili, Y ;
Sudharsan, PT ;
Varalakshmi, P .
TOXICOLOGY, 2005, 215 (1-2) :108-114
[22]   Thymoquinone Supplementation Attenuates Cyclophosphamide-Induced Cardiotoxicity in Rats [J].
Nagi, Mahmoud N. ;
Al-Shabanah, Othman A. ;
Hafez, Mohamed M. ;
Sayed-Ahmed, Mohamed M. .
JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY, 2011, 25 (03) :135-142
[23]  
Nassif WMH, 2013, EXCLI J, V12, P924
[24]   Role of hepatic cytochrome P450s in the pharmacokinetics and toxicity of cyclophosphamide: Studies with the hepatic cytochrome P450 reductase null mouse [J].
Pass, GJ ;
Carrie, D ;
Boylan, N ;
Lorimore, S ;
Wright, E ;
Houston, B ;
Henderson, CJ ;
Wolf, CR .
CANCER RESEARCH, 2005, 65 (10) :4211-4217
[25]   Chemical and antibacterial evaluation of Hypericum triquetrifolium turra [J].
Pistelli, L ;
Bertoli, A ;
Morelli, I ;
Menichini, F ;
Musmanno, RA ;
Di Maggio, T ;
Coratza, G .
PHYTOTHERAPY RESEARCH, 2005, 19 (09) :787-791
[26]   Effect of Codend Circumference on the Size Selection of Square-Mesh Codends in Trawl Fisheries [J].
Sala, Antonello ;
Herrmann, Bent ;
De Carlo, Francesco ;
Lucchetti, Alessandro ;
Brcic, Jure .
PLOS ONE, 2016, 11 (07)
[27]   Inhibition of Gene Expression of Organic Cation/Carnitine Transporter and Antioxidant Enzymes in Oxazaphosphorines-Induced Acute Cardiomyopathic Rat Models [J].
Sayed-Ahmed, Mohamed M. ;
Aldelemy, Meshan Lafi ;
Hafez, Mohamed M. ;
Al-Shabanah, Othman A. .
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2012, 2012
[28]   Cardiotoxicity of cytotoxic drugs [J].
Schimmel, KJM ;
Richel, DJ ;
van den Brink, RBA ;
Guchelaar, HJ .
CANCER TREATMENT REVIEWS, 2004, 30 (02) :181-191
[29]   ESTIMATION OF TOTAL PROTEIN-BOUND AND NONPROTEIN SULFHYDRYL GROUPS IN TISSUE WITH ELLMANS REAGENT [J].
SEDLAK, J ;
LINDSAY, RH .
ANALYTICAL BIOCHEMISTRY, 1968, 25 (1-3) :192-&
[30]   Acute life-threatening toxicity of cancer treatment [J].
Shanholtz, C .
CRITICAL CARE CLINICS, 2001, 17 (03) :483-+